Rekrutierende Studie = ; Fortlaufende Studie = ; Abgeschlossene Studie = ; Förderung durch ein IRDiRC-Mitglied = ; ERN-Mitglied =

Nationale klinische Studie(n)

BELGIEN

VLAAMS BRABANT
LEUVEN

ReSPECT: A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

UZ Leuven - Campus Gasthuisberg

Department of Hematology

Mehr Details

FRANKREICH

AUVERGNE-RHONE-ALPES
GRENOBLE

DexEnceph : Dexamethasone in Herpes Simplex Virus Encephalitis Open Label Randomized Controlled Trial With an Observer-blinded Evaluation at 6 Months (Phase III)

CHU Grenoble Alpes - Site Nord - Hôpital Couple Enfant

Service d'Infectiologie - Maladies infectieuses

Mehr Details

OSTERREICH

TIROL
INNSBRUCK

FURI: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (Phase 3) - AT

Medizinische Universität Innsbruck

Universitätsklinik für Innere Medizin II

Mehr Details

Multinationale klinische Studie(n)

VEREINIGTE STAATEN

New Jersey
JERSEY CITY

FURI: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Scynexis, Inc.

Mehr Details